当前位置: 首页 >> 检索结果
1001. Diffuse Cystic Lung Disease: A Clinical Guide to Recognition and Management.
作者: Alessandro N Franciosi.;Nishant Gupta.;David J Murphy.;Kathryn A Wikenheiser-Brokamp.;Cormac McCarthy.
来源: Chest. 2025年167卷2期529-547页
Diffuse cystic lung diseases (DCLDs) represent a group of pathophysiologically heterogeneous entities that share a common radiologic phenotype of multiple thin-walled pulmonary cysts. DCLDs differ from the typical fibroinflammatory interstitial lung diseases in their epidemiology, clinical presentation, molecular pathogenesis, and therapeutic approaches, making them worthy of a distinct classification. The importance of timely and accurate identification of DCLDs is heightened by the impact on patient management including recent discoveries of targeted therapeutic approaches for some disorders.
1002. Nocturnal Cardiac Arrhythmias in Heart Failure With Obstructive and Central Sleep Apnea.
作者: Christian M Horvath.;Christoph Fisser.;John S Floras.;Samuel Sossalla.;Stella Wang.;George Tomlinson.;Fiona Rankin.;Shoichiro Yatsu.;Clodagh M Ryan.;T Douglas Bradley.;Michael Arzt.; .
来源: Chest. 2024年166卷6期1546-1556页
Both obstructive and central sleep apnea (CSA) may contribute to nocturnal cardiac arrhythmias (NCAs). Data are scarce regarding the prevalence of clinically important nocturnal atrial and ventricular arrythmias in patients with heart failure with reduced ejection fraction (HFrEF) and OSA or CSA.
1003. Extracellular Vesicle-Encapsulated microRNAs and Respiratory Health Among American Indian Participants in the Strong Heart Study.
作者: Christina M Eckhardt.;Haotian Wu.;Gabriela Jackson.;Marisa H Sobel.;Tessa Bloomquist.;Adnan Divjan.;Hadler da Silva.;Lyle G Best.;Shelley Cole.;Jason Umans.;Ying Zhang.;Peter de Hoff.;Louise C Laurent.;Matthew S Perzanowski.;Ke Cheng.;Andrea A Baccarelli.;Tiffany R Sanchez.
来源: Chest. 2025年167卷1期87-97页
American Indian populations have experienced marked disparities in respiratory disease burden. Extracellular vesicle-encapsulated microRNAs (EV-miRNAs) are a novel class of biomarkers that may improve recognition of lung damage in indigenous populations in the United States.
1004. Quantitative Imaging Methods in Combined Pulmonary Fibrosis and Emphysema.
作者: Jennifer M Wang.;Tetsuro Araki.;Vincent Cottin.;MeiLan K Han.;Justin M Oldham.
来源: Chest. 2024年166卷6期1463-1472页
Combined pulmonary fibrosis and emphysema (CPFE) is an underdiagnosed syndrome in which individuals have variable degrees of pulmonary fibrosis and emphysema. Patients with CPFE have high morbidity, including poor exercise tolerance and increased development of comorbidities. CPFE mortality also seems to outpace that of lone emphysema and pulmonary fibrosis. A major limitation to rigorous, large-scale studies of CPFE has been the lack of a precise definition for this syndrome. A 2022 American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association research statement called attention to fundamental gaps in our understanding of CPFE and highlighted the potential use of quantitative imaging techniques to better define CPFE.
1005. Evaluating US Multiple Listing Practices in Lung Transplantation: Unveiling Hidden Disparities.
作者: Adora N Moneme.;Mallory Hunt.;Jacqueline Friskey.;Madeline McCurry.;Dun Jin.;Joshua M Diamond.;Michaela R Anderson.;Emily S Clausen.;Aya Saleh.;Allie Raevsky.;Jason D Christie.;Douglas Schaubel.;Jesse Hsu.;A Russell Localio.;Robert Gallop.;Edward Cantu.
来源: Chest. 2024年166卷6期1442-1454页
Multiple listing (ML) is a practice used to increase the potential for transplant but is controversial due to concerns that it disproportionately benefits patients with greater access to health care resources.
1006. Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
作者: Megan Griffiths.;Catherine E Simpson.;Jun Yang.;Dhananjay Vaidya.;Melanie K Nies.;Stephanie Brandal.;Rachel Damico.;Paul Hassoun.;Dunbar D Ivy.;Eric D Austin.;Michael W Pauciulo.;Katie A Lutz.;Lisa J Martin.;Erika B Rosenzweig.;Raymond L Benza.;William C Nichols.;Cedric Manlhiot.;Allen D Everett.
来源: Chest. 2024年166卷6期1511-1531页
Risk assessment in pulmonary arterial hypertension (PAH) is fundamental to guiding treatment and improved outcomes. Clinical models are excellent at identifying high-risk patients, but leave uncertainty amongst moderate-risk patients.
1007. Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer.
作者: Adam H Fox.;Mariam Alexander.;Jessica A Forcucci.;Gerard A Silvestri.
来源: Chest. 2024年166卷5期1239-1249页
The initial management of patients with lung cancer is growing more complex in the context of an expanding number of precision medicine treatments. These challenges are accompanied by opportunities to deliver more efficacious and less toxic treatments to patients. Indications for these treatments are also expanding, and patients with lung cancer across multiple stages now require biomarker testing. Given their role in the initial management of patients being diagnosed with lung cancer, pulmonologists must have fundamental knowledge regarding the importance, indications, and implications of biomarker testing across the spectrum of histology and stage. The purpose of this review is to provide fundamental knowledge regarding biomarker testing, its incorporation into the initial diagnostic and staging evaluation, and guidance for working within a multidisciplinary team to achieve timely and comprehensive biomarker testing to direct the use of precision medicine treatments.
1008. Longitudinal Changes in Maximal Forced Inspiratory Flow and Clinical Outcomes in Patients With COPD.
作者: Dong Hyun Kim.;Eun-Tae Jeon.;Hyo Jin Lee.;Heemoon Park.;Jung-Kyu Lee.;Eun Young Heo.;Deog Kyeom Kim.;Hyun Woo Lee.
来源: Chest. 2025年167卷1期76-86页
COPD primarily impairs expiratory flow due to progressive airflow obstruction and reduced lung elasticity. Increasing evidence underlines the importance of inspiratory flow as a biomarker for selecting inhaler devices and providing ancillary aerodynamic information.
1009. Occupational Exposure to Charcoal Smoke and Dust, a Major Risk Factor for COPD: A Multiregional Cross-Sectional Study in the Democratic Republic of Congo.
作者: Pierre Olenga Vuvu Lofuta.;Malgorzata Klass.;Nathalie Pauwen.;Augustin Mboko Kipula.;Philippe van de Borne.;Alain Van Muylem.;Silvia Perez-Bogerd.;Gaël Deboeck.
来源: Chest. 2024年166卷6期1334-1346页
Occupational exposure to charcoal smoke and dust is a threat to workers' respiratory systems.
1010. Identifying Risk of Postoperative Cardiorespiratory Complications in OSA.
作者: Maree Azzopardi.;Richard Parsons.;Gemma Cadby.;Stuart King.;Nigel McArdle.;Bhajan Singh.;David R Hillman.
来源: Chest. 2024年166卷5期1197-1208页
Patients with OSA are at increased risk of postoperative cardiorespiratory complications and death. Attempts to stratify this risk have been inadequate, and predictors from large, well-characterized cohort studies are needed.
1011. Decídetexto: Mobile Cessation Support for Latino Adults Who Smoke: A Randomized Clinical Trial.
作者: Francisco Cartujano-Barrera.;Lisa Sanderson Cox.;Delwyn Catley.;Xueya Cai.;Francisco J Diaz.;Evelyn Arana-Chicas.;Arlette Chávez-Iñiguez.;Chinwe Ogedegbe.;Kristi D Graves.;M Patricia Rivera.;Arturo Ponce.;Edward F Ellerbeck.;Ana Paula Cupertino.
来源: Chest. 2025年167卷2期619-629页
Latino adults experience multiple barriers to health care access and treatment that result in tobacco-related disparities. Mobile interventions have the potential to deliver smoking cessation treatment among Latino adults, who show the highest use rates of mobile technologies.
1012. Longitudinal Assessment of Communication With Patient-Reported Outcomes During Lung Cancer Screening.
作者: Christopher G Slatore.;Sara E Golden.;Liana Schweiger.;Ian Ilea.;Donald R Sullivan.;Sean P M Rice.;Renda Soylemez Wiener.;Santanu Datta.;James M Davis.;Anne C Melzer.
来源: Chest. 2025年167卷3期876-891页
Many organizations recommend clinicians use structured communication processes, referred to as shared decision-making, to improve patient-reported outcomes for patients considering lung cancer screening (LCS).
1020. A 62-Year-Old Woman With Cough, Dyspnea, and Diffuse Lung Nodules.
作者: Felix W Wireko.;Erin S DeMartino.;Lara A Walkoff.;Jennifer M Boland.;Jay H Ryu.
来源: Chest. 2024年166卷2期e61-e65页
A 62-year-old woman came to our hospital with worsening cough and dyspnea over the preceding week, during which time she had been treated with azithromycin and prednisone for suspected pneumonia. She had no fever, chills, or sweats, but her cough had become productive of clear to blood-tinged phlegm during the interval. Medical history was significant for insulin-dependent diabetes mellitus and OSA. She had quit smoking 44 years earlier and had no history of lung disease. She was a bank teller residing in southeastern Minnesota and described no relevant inhalational or environmental exposures, drug use, aspiration, or travels preceding her illness.
|